

Qin Cheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1329671/publications.pdf>

Version: 2024-02-01

121
papers

7,651
citations

50276

46
h-index

58581

82
g-index

123
all docs

123
docs citations

123
times ranked

5506
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative genomics of the neglected human malaria parasite <i>Plasmodium vivax</i> . <i>Nature</i> , 2008, 455, 757-763.	27.8	756
2	A Large Proportion of <i>P. falciparum</i> Isolates in the Amazon Region of Peru Lack <i>pfhrp2</i> and <i>pfhrp3</i> : Implications for Malaria Rapid Diagnostic Tests. <i>PLoS ONE</i> , 2010, 5, e8091.	2.5	382
3	Mutations in <i>Plasmodium falciparum</i> Cytochrome b That Are Associated with Atovaquone Resistance Are Located at a Putative Drug-Binding Site. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2100-2108.	3.2	340
4	A large proportion of asymptomatic <i>Plasmodium</i> infections with low and sub-microscopic parasite densities in the low transmission setting of Temotu Province, Solomon Islands: challenges for malaria diagnostics in an elimination setting. <i>Malaria Journal</i> , 2010, 9, 254.	2.3	243
5	Genetic Diversity of <i>Plasmodium falciparum</i> Histidine-Rich Protein 2 (PfHRP2) and Its Effect on the Performance of PfHRP2-Based Rapid Diagnostic Tests. <i>Journal of Infectious Diseases</i> , 2005, 192, 870-877.	4.0	240
6	<i>stevor</i> and <i>rif</i> are <i>Plasmodium falciparum</i> multicopy gene families which potentially encode variant antigens. <i>Molecular and Biochemical Parasitology</i> , 1998, 97, 161-176.	1.1	230
7	Artemisinin-Induced Dormancy in <i>Plasmodium falciparum</i> : Duration, Recovery Rates, and Implications in Treatment Failure. <i>Journal of Infectious Diseases</i> , 2010, 202, 1362-1368.	4.0	195
8	Chloroquine Resistant <i>Plasmodium vivax</i> : In Vitro Characterisation and Association with Molecular Polymorphisms. <i>PLoS ONE</i> , 2007, 2, e1089.	2.5	187
9	<i>Plasmodium falciparum</i> parasites lacking histidine-rich protein 2 and 3: a review and recommendations for accurate reporting. <i>Malaria Journal</i> , 2014, 13, 283.	2.3	176
10	Effect of Sequence Variation in <i>Plasmodium falciparum</i> Histidine-Rich Protein 2 on Binding of Specific Monoclonal Antibodies: Implications for Rapid Diagnostic Tests for Malaria. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2773-2778.	3.9	155
11	Measurement of <i>Plasmodium falciparum</i> Growth Rates in Vivo: A Test of Malaria Vaccines. <i>American Journal of Tropical Medicine and Hygiene</i> , 1997, 57, 495-500.	1.4	148
12	Relapses of <i>Plasmodium vivax</i> Infection Result from Clonal Hypnozoites Activated at Predetermined Intervals. <i>Journal of Infectious Diseases</i> , 2007, 195, 934-941.	4.0	144
13	Global sequence variation in the histidine-rich proteins 2 and 3 of <i>Plasmodium falciparum</i> : implications for the performance of malaria rapid diagnostic tests. <i>Malaria Journal</i> , 2010, 9, 129.	2.3	136
14	Major Threat to Malaria Control Programs by <i>Plasmodium falciparum</i> Lacking Histidine-Rich Protein 2, Eritrea. <i>Emerging Infectious Diseases</i> , 2018, 24, 462-470.	4.3	135
15	Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of <i>Plasmodium falciparum</i> in non-immune volunteers. <i>Vaccine</i> , 2000, 18, 1925-1931.	3.8	132
16	Systematic Review of Sub-microscopic <i>P. vivax</i> Infections: Prevalence and Determining Factors. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e3413.	3.0	114
17	Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. <i>Malaria Journal</i> , 2013, 12, 112.	2.3	112
18	Therapeutic Efficacies of Artesunate-Sulfadoxine-Pyrimethamine and Chloroquine-Sulfadoxine-Pyrimethamine in Vivax Malaria Pilot Studies: Relationship to <i>Plasmodium vivax</i> <i>dhfr</i> Mutations. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3947-3953.	3.2	111

#	ARTICLE	IF	CITATIONS
19	Role of <i>pfmdr1</i> Amplification and Expression in Induction of Resistance to Artemisinin Derivatives in <i>Plasmodium falciparum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2455-2464.	3.2	108
20	<i>Plasmodium knowlesi</i> in Human, Indonesian Borneo. <i>Emerging Infectious Diseases</i> , 2010, 16, 672-674.	4.3	104
21	High diversity and rapid changeover of expressed var genes during the acute phase of <i>Plasmodium falciparum</i> infections in human volunteers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 10689-10694.	7.1	103
22	Novel molecular diagnostic tools for malaria elimination: a review of options from the point of view of high-throughput and applicability in resource limited settings. <i>Malaria Journal</i> , 2016, 15, 88.	2.3	102
23	<i>pfprt</i> Allelic Types with Two Novel Amino Acid Mutations in Chloroquine-Resistant <i>Plasmodium falciparum</i> Isolates from the Philippines. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3500-3505.	3.2	101
24	Sulfadoxine Resistance in <i>Plasmodium vivax</i> Is Associated with a Specific Amino Acid in Dihydropteroate Synthase at the Putative Sulfadoxine-Binding Site. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2214-2222.	3.2	100
25	<i>Plasmodium vivax</i> synonymous substitution frequencies, evolution and population structure deduced from diversity in AMA 1 and MSP 1 genes. <i>Molecular and Biochemical Parasitology</i> , 2000, 108, 53-66.	1.1	97
26	Sequence analysis of the apical membrane antigen I (AMA-1) of <i>plasmodium vivax</i> . <i>Molecular and Biochemical Parasitology</i> , 1994, 65, 183-187.	1.1	86
27	A review of the WHO malaria rapid diagnostic test product testing programme (2008–2018): performance, procurement and policy. <i>Malaria Journal</i> , 2019, 18, 387.	2.3	86
28	Artemisinin-induced parasite dormancy: a plausible mechanism for treatment failure. <i>Malaria Journal</i> , 2011, 10, 56.	2.3	78
29	AMINO ACID MUTATIONS IN PLASMODIUM VIVAX DHFR AND DHPS FROM SEVERAL GEOGRAPHICAL REGIONS AND SUSCEPTIBILITY TO ANTIFOLATE DRUGS. <i>American Journal of Tropical Medicine and Hygiene</i> , 2006, 75, 617-621.	1.4	76
30	Evolution of Resistance to Sulfadoxine-Pyrimethamine in <i>Plasmodium falciparum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2116-2123.	3.2	73
31	Laboratory demonstration of a prozone-like effect in HRP2-detecting malaria rapid diagnostic tests: implications for clinical management. <i>Malaria Journal</i> , 2011, 10, 286.	2.3	71
32	Phenotypic and genotypic characterisation of drug-resistant <i>Plasmodium vivax</i> . <i>Trends in Parasitology</i> , 2012, 28, 522-529.	3.3	70
33	Artemisinin resistance in <i>Plasmodium falciparum</i> : A process linked to dormancy?. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2012, 2, 249-255.	3.4	69
34	Limited Polymorphism in the Dihydropteroate Synthetase Gene (<i>dhps</i>) of <i>Plasmodium vivax</i> Isolates from Thailand. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4393-4395.	3.2	63
35	Phenotypic Changes in Artemisinin-Resistant <i>Plasmodium falciparum</i> Lines <i>In Vitro</i> : Evidence for Decreased Sensitivity to Dormancy and Growth Inhibition. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 428-431.	3.2	63
36	Fatty Acid Synthesis and Pyruvate Metabolism Pathways Remain Active in Dihydroartemisinin-Induced Dormant Ring Stages of <i>Plasmodium falciparum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4773-4781.	3.2	62

#	ARTICLE	IF	CITATIONS
37	Mitochondrial Membrane Potential in a Small Subset of Artemisinin-Induced Dormant <i>Plasmodium falciparum</i> Parasites In Vitro. <i>Journal of Infectious Diseases</i> , 2015, 212, 426-434.	4.0	62
38	Transcription and Expression of <i>Plasmodium falciparum</i> Histidine-Rich Proteins in Different Stages and Strains: Implications for Rapid Diagnostic Tests. <i>PLoS ONE</i> , 2011, 6, e22593.	2.5	61
39	The 42-kilodalton rhoptry-associated protein of <i>Plasmodium falciparum</i> . <i>Molecular and Biochemical Parasitology</i> , 1992, 50, 139-149.	1.1	59
40	Identification of Optimal Epitopes for <i>Plasmodium falciparum</i> Rapid Diagnostic Tests That Target Histidine-Rich Proteins 2 and 3. <i>Journal of Clinical Microbiology</i> , 2012, 50, 1397-1405.	3.9	57
41	Sequence Polymorphisms in <i>pfcrtr</i> Are Strongly Associated with Chloroquine Resistance in <i>Plasmodium falciparum</i> . <i>Journal of Infectious Diseases</i> , 2001, 183, 1543-1545.	4.0	56
42	Mutations in Cytochrome b Resulting in Atovaquone Resistance Are Associated with Loss of Fitness in <i>Plasmodium falciparum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 2435-2441.	3.2	53
43	Differential Changes in <i>Plasmodium falciparum</i> var Transcription during Adaptation to Culture. <i>Journal of Infectious Diseases</i> , 2007, 195, 748-755.	4.0	53
44	Genetic diversity of the DBL α region in <i>Plasmodium falciparum</i> var genes among Asia-Pacific isolates. <i>Molecular and Biochemical Parasitology</i> , 2002, 120, 117-126.	1.1	52
45	Challenges for achieving safe and effective radical cure of <i>Plasmodium vivax</i> : a round table discussion of the APMEN Vivax Working Group. <i>Malaria Journal</i> , 2017, 16, 141.	2.3	52
46	Amino acid mutations in <i>Plasmodium vivax</i> DHFR and DHPS from several geographical regions and susceptibility to antifolate drugs. <i>American Journal of Tropical Medicine and Hygiene</i> , 2006, 75, 617-21.	1.4	52
47	Sequence variation in the circumsporozoite protein gene of <i>Plasmodium vivax</i> appears to be regionally biased. <i>Molecular and Biochemical Parasitology</i> , 1994, 68, 45-52.	1.1	50
48	Implications of Parasites Lacking <i>Plasmodium falciparum</i> Histidine-Rich Protein 2 on Malaria Morbidity and Control When Rapid Diagnostic Tests Are Used for Diagnosis. <i>Journal of Infectious Diseases</i> , 2017, 215, 1156-1166.	4.0	46
49	Evaluation of the pyrogenic threshold for <i>Plasmodium falciparum</i> malaria in naive individuals. <i>American Journal of Tropical Medicine and Hygiene</i> , 2002, 66, 467-473.	1.4	45
50	Levels of Chloroquine Resistance in <i>Plasmodium falciparum</i> Are Determined by Loci Other than <i>pfcrtr</i> and <i>pfmdr1</i> . <i>Journal of Infectious Diseases</i> , 2002, 185, 405-406.	4.0	44
51	<i>Plasmodium falciparum</i> genetic diversity can be characterised using the polymorphic merozoite surface antigen 2 (MSA-2) gene as a single locus marker. <i>Molecular and Biochemical Parasitology</i> , 1994, 63, 203-212.	1.1	43
52	Population genetics of <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> and asymptomatic malaria in Temotu Province, Solomon Islands. <i>Malaria Journal</i> , 2013, 12, 429.	2.3	42
53	Origin and Dissemination of Chloroquine-Resistant <i>Plasmodium falciparum</i> with Mutant <i>pfcrtr</i> Alleles in the Philippines. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2102-2105.	3.2	40
54	Assessing the Genetic Diversity of the Aldolase Genes of <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> and Its Potential Effect on Performance of Aldolase-Detecting Rapid Diagnostic Tests. <i>Journal of Clinical Microbiology</i> , 2006, 44, 4547-4549.	3.9	39

#	ARTICLE	IF	CITATIONS
55	Switching rates of <i>Plasmodium falciparum</i> var genes: faster than we thought?. <i>Trends in Parasitology</i> , 2003, 19, 202-208.	3.3	38
56	Sensitive Detection of <i>Plasmodium vivax</i> Using a High-Throughput, Colourimetric Loop Mediated Isothermal Amplification (HtLAMP) Platform: A Potential Novel Tool for Malaria Elimination. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004443.	3.0	38
57	Dimorphism of the C terminus of the <i>Plasmodium vivax</i> merozoite surface protein 1. <i>Molecular and Biochemical Parasitology</i> , 1995, 70, 217-219.	1.1	36
58	Modeling the Development of Acquired Clinical Immunity to <i>Plasmodium falciparum</i> Malaria. <i>Infection and Immunity</i> , 2004, 72, 6538-6545.	2.2	35
59	Multiple origins of resistance-conferring mutations in <i>Plasmodium vivax</i> dihydrofolate reductase. <i>Malaria Journal</i> , 2008, 7, 72.	2.3	35
60	Prevalence of <i>Plasmodium falciparum</i> lacking histidine-rich proteins 2 and 3: a systematic review. <i>Bulletin of the World Health Organization</i> , 2020, 98, 558-568F.	3.3	35
61	The dihydrofolate reductase domain of rodent malarias: point mutations and pyrimethamine resistance. <i>Molecular and Biochemical Parasitology</i> , 1994, 65, 361-363.	1.1	33
62	A simple, high-throughput, colourimetric, field applicable loop-mediated isothermal amplification (HtLAMP) assay for malaria elimination. <i>Malaria Journal</i> , 2015, 14, 335.	2.3	33
63	Operational research to inform a sub-national surveillance intervention for malaria elimination in Solomon Islands. <i>Malaria Journal</i> , 2012, 11, 101.	2.3	32
64	Circulating antibodies against <i>Plasmodium falciparum</i> histidine-rich proteins 2 interfere with antigen detection by rapid diagnostic tests. <i>Malaria Journal</i> , 2014, 13, 480.	2.3	31
65	Deamplification of <i>pfmdr1</i> -Containing Amplicon on Chromosome 5 in <i>Plasmodium falciparum</i> Is Associated with Reduced Resistance to Artemisinin Acid In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3395-3401.	3.2	30
66	Pan- <i>Plasmodium</i> band sensitivity for <i>Plasmodium falciparum</i> detection in combination malaria rapid diagnostic tests and implications for clinical management. <i>Malaria Journal</i> , 2015, 14, 115.	2.3	30
67	Single Domain Antibodies as New Biomarker Detectors. <i>Diagnostics</i> , 2017, 7, 52.	2.6	29
68	The changing epidemiology of <i>Plasmodium vivax</i> : Insights from conventional and novel surveillance tools. <i>PLoS Medicine</i> , 2021, 18, e1003560.	8.4	28
69	Isolation and characterization of malaria PfHRP2 specific VNAR antibody fragments from immunized shark phage display library. <i>Malaria Journal</i> , 2018, 17, 383.	2.3	26
70	Impact of <i>Plasmodium falciparum</i> gene deletions on malaria rapid diagnostic test performance. <i>Malaria Journal</i> , 2020, 19, 392.	2.3	25
71	Nitric Oxide Production and Nitric Oxide Synthase Activity in Malaria-Exposed Papua New Guinean Children and Adults Show Longitudinal Stability and No Association with Parasitemia. <i>Infection and Immunity</i> , 2004, 72, 6932-6938.	2.2	24
72	Defining the next generation of <i>Plasmodium vivax</i> diagnostic tests for control and elimination: Target product profiles. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005516.	3.0	24

#	ARTICLE	IF	CITATIONS
73	An Analytical Method for Assessing Stage-Specific Drug Activity in Plasmodium vivax Malaria: Implications for Ex Vivo Drug Susceptibility Testing. PLoS Neglected Tropical Diseases, 2012, 6, e1772.	3.0	23
74	An assessment of false positive rates for malaria rapid diagnostic tests caused by non-Plasmodium infectious agents and immunological factors. PLoS ONE, 2018, 13, e0197395.	2.5	23
75	<i>Plasmodium falciparum</i> Histidine-Rich Protein 2 and 3 Gene Deletions in Strains from Nigeria, Sudan, and South Sudan. Emerging Infectious Diseases, 2021, 27, 471-479.	4.3	23
76	Genetic diversity and population structure of Plasmodium vivax in Central China. Malaria Journal, 2014, 13, 262.	2.3	22
77	A Sensitive, Colorimetric, High-Throughput Loop-Mediated Isothermal Amplification Assay for the Detection of Plasmodium knowlesi. American Journal of Tropical Medicine and Hygiene, 2016, 95, 120-122.	1.4	21
78	Production and characterization of specific monoclonal antibodies binding the Plasmodium falciparum diagnostic biomarker, histidine-rich protein 2. Malaria Journal, 2014, 13, 277.	2.3	20
79	Molecular surveillance reveals the presence of pfhrp2 and pfhrp3 gene deletions in Plasmodium falciparum parasite populations in Uganda, 2017–2019. Malaria Journal, 2020, 19, 300.	2.3	19
80	Comparison of Rapid Diagnostic Tests for the Detection of Plasmodium vivax Malaria in South Korea. PLoS ONE, 2013, 8, e64353.	2.5	18
81	Dormant <i>Plasmodium falciparum</i> Parasites in Human Infections Following Artesunate Therapy. Journal of Infectious Diseases, 2021, 223, 1631-1638.	4.0	18
82	Can estimates of antimalarial efficacy from field studies be improved?. Trends in Parasitology, 2008, 24, 68-73.	3.3	17
83	Dihydrofolate-Reductase Mutations in Plasmodium knowlesi Appear Unrelated to Selective Drug Pressure from Putative Human-To-Human Transmission in Sabah, Malaysia. PLoS ONE, 2016, 11, e0149519.	2.5	17
84	Limitations of rapid diagnostic tests in malaria surveys in areas with varied transmission intensity in Uganda 2017-2019: Implications for selection and use of HRP2 RDTs. PLoS ONE, 2020, 15, e0244457.	2.5	17
85	Correlation between Cyclin Dependent Kinases and Artemisinin-Induced Dormancy in Plasmodium falciparum In Vitro. PLoS ONE, 2016, 11, e0157906.	2.5	16
86	Evidence of cross-contamination among laboratory lines of Plasmodium berghei1Note: Nucleotide sequence data reported in this paper have been submitted to the Genbank, data base with accession numbers U65085–65088.1. Molecular and Biochemical Parasitology, 1997, 84, 143-147.	1.1	15
87	Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor. Malaria Journal, 2019, 18, 140.	2.3	15
88	Epidemiology of mutant Plasmodium falciparum parasites lacking histidine-rich protein 2/3 genes in Eritrea 2 years after switching from HRP2-based RDTs. Scientific Reports, 2021, 11, 21082.	3.3	15
89	No Genetic Bottleneck in <i>Plasmodium falciparum</i> Wild-Type Pf crt Alleles Reemerging in Hainan Island, China, following High-Level Chloroquine Resistance. Antimicrobial Agents and Chemotherapy, 2008, 52, 345-347.	3.2	14
90	Identification of a common Plasmodium epitope (CPE) recognised by a pan-specific inhibitory monoclonal antibody. Molecular and Biochemical Parasitology, 1991, 49, 73-82.	1.1	13

#	ARTICLE	IF	CITATIONS
91	Defining the Role of Mutations in <i>Plasmodium vivax</i> Dihydrofolate Reductase-Thymidylate Synthase Gene Using an Episomal <i>Plasmodium falciparum</i> Transfection System. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3927-3932.	3.2	13
92	Malaria and other vector-borne infection surveillance in the U.S. Department of Defense Armed Forces Health Surveillance Center-Global Emerging Infections Surveillance program: review of 2009 accomplishments. <i>BMC Public Health</i> , 2011, 11, S9.	2.9	13
93	VivaxGEN: An open access platform for comparative analysis of short tandem repeat genotyping data in <i>Plasmodium vivax</i> populations. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005465.	3.0	13
94	DETECTION SENSITIVITY AND QUANTITATION OF PLASMODIUM FALCIPARUM VAR GENE TRANSCRIPTS BY REAL-TIME RT-PCR IN COMPARISON WITH CONVENTIONAL RT-PCR. <i>American Journal of Tropical Medicine and Hygiene</i> , 2006, 75, 212-218.	1.4	13
95	Interrupting Malaria Transmission: Quantifying the Impact of Interventions in Regions of Low to Moderate Transmission. <i>PLoS ONE</i> , 2010, 5, e15149.	2.5	12
96	Aldolase genes of <i>Plasmodium</i> species. <i>Molecular and Biochemical Parasitology</i> , 2001, 113, 327-330.	1.1	11
97	Pyrimethamine-sulfadoxine resistance in <i>Plasmodium falciparum</i> must be delayed in Africa. <i>Trends in Parasitology</i> , 2002, 18, 293.	3.3	11
98	Physical Linkage to Drug Resistance Genes Results in Conservation of var Genes among West Pacific <i>Plasmodium falciparum</i> Isolates. <i>Journal of Infectious Diseases</i> , 2006, 194, 939-948.	4.0	11
99	Detection sensitivity and quantitation of <i>Plasmodium falciparum</i> var gene transcripts by real-time RT-PCR in comparison with conventional RT-PCR. <i>American Journal of Tropical Medicine and Hygiene</i> , 2006, 75, 212-8.	1.4	11
100	Characterization of the Antibody Response against <i>Plasmodium falciparum</i> Erythrocyte Membrane Protein 1 in Human Volunteers. <i>Infection and Immunity</i> , 2007, 75, 5967-5973.	2.2	10
101	A Novel <i>Plasmodium falciparum</i> Expression System for Assessing Antifolate Resistance Caused by Mutant <i>P. vivax</i> Dihydrofolate Reductase-Thymidylate Synthase. <i>Journal of Infectious Diseases</i> , 2007, 196, 467-474.	4.0	10
102	Genetic mutations in <i>pfprt</i> and <i>pfmdr1</i> at the time of artemisinin combination therapy introduction in South Pacific islands of Vanuatu and Solomon Islands. <i>Malaria Journal</i> , 2014, 13, 406.	2.3	10
103	Research note Codon usage in <i>Plasmodium vivax</i> nuclear genes. <i>International Journal for Parasitology</i> , 1999, 29, 445-449.	3.1	9
104	Sequence diversity in rodent malaria of the Pfs28 ookinete surface antigen homologs. <i>Molecular and Biochemical Parasitology</i> , 2000, 110, 429-434.	1.1	9
105	Short report: Molecular evaluation of the efficacy of chloroquine treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in East Timor. <i>American Journal of Tropical Medicine and Hygiene</i> , 2002, 67, 64-66.	1.4	9
106	<i>Plasmodium falciparum</i> infection dynamics and transmission potential following treatment with sulfadoxine-pyrimethamine. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 47-51.	3.0	8
107	Screening strategies and laboratory assays to support <i>Plasmodium falciparum</i> histidine-rich protein deletion surveillance: where we are and what is needed. <i>Malaria Journal</i> , 2022, 21, .	2.3	8
108	Efficacy of chloroquine in the treatment of uncomplicated <i>Plasmodium falciparum</i> infection in East Timor, 2000. <i>Acta Tropica</i> , 2003, 88, 87-90.	2.0	7

#	ARTICLE	IF	CITATIONS
109	Functional Analysis of Plasmodium vivax Dihydrofolate Reductase-Thymidylate Synthase Genes through Stable Transformation of Plasmodium falciparum. PLoS ONE, 2012, 7, e40416.	2.5	7
110	Plasmodium falciparum and Plasmodium vivax Demonstrate Contrasting Chloroquine Resistance Reversal Phenotypes. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	7
111	The Utility of Malaria Rapid Diagnostic Tests as a Tool in Enhanced Surveillance for Malaria Elimination in Vanuatu. PLoS ONE, 2016, 11, e0167136.	2.5	7
112	Genetic mutations in Plasmodium falciparum and Plasmodium vivax dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) in Vanuatu and Solomon Islands prior to the introduction of artemisinin combination therapy. Malaria Journal, 2014, 13, 402.	2.3	6
113	Polymorphisms in Plasmodium falciparum Kelch 13 and P. vivax Kelch 12 Genes in Parasites Collected from Three South Pacific Countries Prior to Extensive Exposure to Artemisinin Combination Therapies. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	5
114	Genetic diversity and genetic relatedness in Plasmodium falciparum parasite population in individuals with uncomplicated malaria based on microsatellite typing in Eastern and Western regions of Uganda, 2019–2020. Malaria Journal, 2021, 20, 242.	2.3	5
115	EFFICACY OF SULFADOXINE-PYRIMETHAMINE IN THE TREATMENT OF UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA IN EAST TIMOR. American Journal of Tropical Medicine and Hygiene, 2006, 74, 361-366.	1.4	4
116	Efficacy of sulfadoxine-pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria in East Timor. American Journal of Tropical Medicine and Hygiene, 2006, 74, 361-6.	1.4	4
117	The Development of Single Domain Antibodies for Diagnostic and Therapeutic Applications. , 2018, , .		3
118	Malaria in Pregnancy in the Solomon Islands: Barriers to Prevention and Control. American Journal of Tropical Medicine and Hygiene, 2008, 78, 449-454.	1.4	3
119	Modelling the epidemiology of malaria and spread of HRP2-negative Plasmodium falciparum following the replacement of HRP2-detecting rapid diagnostic tests. PLOS Global Public Health, 2022, 2, e0000106.	1.6	3
120	Cytoplasmic and periplasmic expression of recombinant shark VNAR antibody in Escherichia coli. Preparative Biochemistry and Biotechnology, 2019, 49, 315-327.	1.9	2
121	Plasmodium falciparum Rapid Test Failures Threaten Diagnosis and Treatment of U.S. Military Personnel. Military Medicine, 2019, 185, e1-e4.	0.8	0